Research on the Warburg effect, a hallmark metabolic reprogramming in tumors, has identified multiple therapeutic agents targeting glucose metabolism including GLUT‐1 inhibitors with potential anticancer activity [29].  GLUT‐1, a key protein in glycolysis, was found to be downregulated in HCT116PRDX1‐KD cells, suggesting that PRDX1 may regulate the expression of GLUT‐1 in cancer cells. The gene discussed is PRDX1; the disease is cancer.